Clinical trials: Ritonavir
HIV Infections
Comparison of GW433908/Ritonavir to Nelfinavir When Used With Abacavir and Lamivudine in Patients That Have Not Taken Antiretroviral Drugs
The purpose of this study is to compare virus response to GW433908/ritonavir (RTV) to viral response to nelfinavir (NFV) when used with abacavir (ABC)/lamivudine (3TC) in patients that have not taken antiretroviral (ART) drugs.
- Trial name
- NCT00009061
- Testing
- Ritonavir, Abacavir sulfate, Nelfinavir mesylate
- Where
- 37 sites in United States
- Volunteers
- 624 people
- Sponsor
- Glaxo Wellcome
Chronic Hepatitis C Infection
A Study to Evaluate Chronic Hepatitis C Infection in Adult Transplant Recipients
The purpose of this study is to evaluate the safety and efficacy of ABT-450/r/ABT-267 with or without ABT-333 and with or without ribavirin (RBV) in adult liver or renal transplant recipients with hepatitis C virus (HCV) genotype…
- Trial name
- CORAL-I (NCT01782495)
- Testing
- ombitasvir/paritaprevir/ritonavir and dasabuvir, ombitasvir/paritaprevir/ritonavir, ribavirin
- Volunteers
- 129 people
- Sponsor
- AbbVie
Healthy
Pharmacokinetics of Tipranavir/Ritonavir and Its Metabolites in Healthy Male Subjects
Study to evaluate the pharmacokinetics of Tipranavir and its metabolites including excretion and mass balance of parent compound and radioactivity at steady-state; to isolate, identify and quantify major metabolites of tipranavir…
- Trial name
- NCT02253797
- Testing
- 14C-Tipranavir, Tipranavir, Ritonavir
- Volunteers
- healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Healthy Volunteer
GSK1349572 Drug Interaction Study With Atazanavir/Ritonavir and Atazanavir
The purpose of this study is to compare the amount of GSK1349572 (study drug) in the blood when given with and without atazanavir/ritonavir or atazanavir and to compare the blood levels of atazanavir when given with GSK1349572 to…
- Trial name
- NCT00883935
- Testing
- GSK1349572, Atazanavir 300 mg, Atazanavir 400 mg
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
HIV Infection
Study Of Chemokine Coreceptor 5 (CCR5) Antagonist GW873140 In R5/X4-Tropic Treatment-Experienced HIV-Infected Subjects
The purpose of this study is to evaluate the safety and efficacy of the CCR5 antagonist GW873140 or placebo in combination with an optimized background regimen in treatment-experienced HIV-infected subjects with R5/X4-tropic virus
- Trial name
- NCT00197197
- Testing
- GW873140
- Where
- 12 sites in United States, Belgium
- Volunteers
- 18 people
- Sponsor
- GlaxoSmithKline
Infection, Human Immunodeficiency Virus
DDI Study of BMS-663068 With Etravirine (ETR) and/or Darunavir (DVR) + Ritonavir (RTV)
The purpose of this study is to determine if there is an interaction in healthy subjects taking BMS-663068 with Darunavir/Ritonavir and/or Etravirine.
- Trial name
- NCT02063360
- Testing
- BMS-663068, Darunavir (DRV), Ritonavir (RTV)
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- ViiV Healthcare
Healthy
Pharmacokinetic Study in Healthy Adult Volunteers to Assess the Interactions Between Steady-State Tipranavir and Atazanavir in the Presence of Ritonavir
Study to investigate the effects of steady-state TPV/r (500 mg/100 mg BID) on the single-dose and steady-state pharmacokinetics of Atazanavir (300 mg QD) co-administered with Ritonavir (100 mg).
- Trial name
- NCT02253836
- Testing
- Tipranavir, Ritonavir, Atazanavir
- Volunteers
- 21 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Human Immunodeficiency Virus (HIV) Infections, Acquired Immunodeficiency Syndrome (AIDS) Virus
A Clinical Trial Comparing the Efficacy of Darunavir/Ritonavir Monotherapy Versus a Triple Combination Therapy Containing Darunavir/Ritonavir and 2 Nucleoside/Nucleotide Reverse Transcriptase Inhibitors in Patients With Undetectable Plasma HIV-1 RNA on Current Treatment
The purpose of this study is to compare the efficacy, safety and tolerability of darunavir/ritonavir 800/100 mg monotherapy with a triple combination therapy containing darunavir/ritonavir 800/100 mg and 2 nucleoside/nucleotide…
- Trial name
- PROTEA (NCT01448707)
- Testing
- Darunavir, Ritonavir
- Where
- 34 sites in Austria, Belgium and 11 more
- Volunteers
- 274 people
- Sponsor
- Janssen-Cilag International NV
Chronic Hepatitis C Virus
Drug Use-results Survey in Patients Infected With Hepatitis C Virus Genotype 1
The main objective of this study is to evaluate the safety and effectiveness of paritaprevir/ritonavir/ombitasvir used for patients infected with HCV genotype 1 in daily practice in Japan.
- Trial name
- NCT02629172
- Where
- 388 sites in Japan
- Volunteers
- 3,043 people
- Sponsor
- AbbVie
Healthy
Effects of Tipranavir (TPV) and Ritonavir (RTV) on the Pharmacokinetic Characteristics of Tenofovir Disoproxil Fumarate in Healthy Volunteers
Study to characterise the effects of two dose combinations of tipranavir/ritonavir (TPV 500 mg/RTV 100 mg and TPV 750 mg/RTV 200 mg) administered BID, on the pharmacokinetics of tenofovir disoproxil fumarate as well as the…
- Trial name
- NCT02251145
- Testing
- Tipranavir low dose, Tipranavir high dose, Ritonavir low dose
- Volunteers
- 49 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Chronic Hepatitis C Infection
A Study of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With or Without Sofosbuvir and Ribavirin in Direct-Acting Antiviral Agent Treatment-Experienced Adults With Chronic Hepatitis C Virus Infection
The purpose of this study is to evaluate the safety and efficacy of ombitasvir/paritaprevir/ritonavir and dasabuvir with or without sofosbuvir (SOF) and ribavirin (RBV) in DAA treatment-experienced adults with Genotype 1 Chronic…
- Trial name
- NCT02356562
- Testing
- ombitasvir/paritaprevir/ritonavir and dasabuvir, Sofosbuvir, Ribavirin
- Volunteers
- 29 people
- Sponsor
- AbbVie
Chronic Hepatitis C
Real World Evidence of the Effectiveness of Paritaprevir/Ritonavir (r) - Ombitasvir, + Dasabuvir Without Ribavirin in Participants With Chronic Hepatitis C and Compensated Liver Cirrhosis in the Russian Federation
This prospective, multi-center, observational study is designed to assess the real world effectiveness of paritaprevir/r - ombitasvir with dasabuvir (3DAA [direct-acting antiviral agent] ABBVIE REGIMEN) without ribavirin (RBV)…
- Trial name
- CITRIN (NCT03053180)
- Where
- 7 sites in Russia
- Volunteers
- 60 people
- Sponsor
- AbbVie
Chronic Hepatitis C Virus
Study of Ombitasvir/Paritaprevir/Ritonavir in Japanese Adults With Genotype 1b Chronic Hepatitis C Virus (HCV) Infection With End Stage Renal Disease (ESRD) on Hemodialysis (HD)
The purpose of this multicenter, single-arm, combination-drug study, which includes 12 weeks of treatment and 24 weeks of follow-up, is to evaluate the safety, efficacy and pharmacokinetics of ombitasvir/paritaprevir/ritonavir in…
- Trial name
- GIFT-R (NCT02806362)
- Testing
- Ombitasvir/paritaprevir/ritonavir
- Sponsor
- AbbVie
Healthy
A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of TMC647055 in Combination With Ritonavir (Part 1) and the Co-administration of TMC435, TMC647055 and Ritonavir (Part 2) in Healthy Japanese Participants
The purpose of the study is to investigate the safety, tolerability, and pharmacokinetics of TMC647055 in combination with ritonavir (Part 1); potential pharmacokinetic drug-drug interactions between TMC435 and the combination of…
- Trial name
- NCT02064842
- Testing
- TMC647055, TMC435, Ritonavir (RTV)
- Where
- United Kingdom
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Janssen R&D Ireland
HIV-1
Early Access to Low-dose Ritonavir (TMC114/r) and Other Antiretrovirals (ARVs) for Treatment-naive or Early Treatment Experienced in HIV-1 Patients
The purpose of this study is to provide early access to TMC114 administered with low-dose ritonavir (TMC114/r) and other antiretrovirals (ARVs) for HIV-1-infected patients who have not received previous HIV treatment or have…
- Trial name
- NCT01702090
- Testing
- TMC114/ritonavir
- Where
- Taiwan
- Volunteers
- 10 people
- Sponsor
- Janssen-Cilag Ltd.
Healthy Volunteer
A Study of The Relative Bioavailability of Ritonavir-Boosted Danoprevir Fixed Dose Combination Tablets in Healthy Volunteers
This randomized, open-label, crossover study will evaluate the relative bioavailability of ritonavir-boosted danoprevir fixed dose combination tablets (FDC) as compared to ad hoc combination of reference tablets of danoprevir and…
- Trial name
- NCT01592318
- Testing
- danoprevir, ritonavir
- Where
- New Zealand
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- Hoffmann-La Roche
HIV Infections
Observational Non-interventional Study (Anwendungsbeobachtung) With Aptivus® (Tipranavir) in HIV-infected Patients.
This observational study is supposed to assess (under conditions of clinical practice in daily routine) whether treatment with Aptivus (tipranavir) in combination with low-dose Norvir (ritonavir) will durably suppress viral load…
- Trial name
- NCT00531206
- Testing
- Tipranavir, Ritonavir
- Where
- 27 sites in Germany
- Volunteers
- 65 people
- Sponsor
- Boehringer Ingelheim
Chronic Hepatitis C
Efficacy and Safety of Danoprevir/r + PR 12-week Triple Therapy in Treatment-Naive, Non-Cirrhotic, G1 CHC China II
The purpose of this study is to evaluate the Efficacy, Safety and Pharmacokinetics of Ritonavir-boosted Danoprevir (ASC08) in Combination with Peg-IFN and RBV in Treatment-Naive Non-Cirrhotic Patients Who Have Chronic Hepatitis…
- Trial name
- NCT03020004
- Testing
- Danoprevir, Ritonavir, peginterferon alfa-2a
- Volunteers
- 70 people
- Sponsor
- Ascletis Pharmaceuticals Co., Ltd.
Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), Coronavirus Disease 2019 (COVID-19)
A Study to Learn About the Medicine Called Nirmatrelvir Used in Combination With Ritonavir in People With Weakened Immune Systems or at Increased Risk for Poor Outcomes Who Are Hospitalized Due to Severe COVID-19
A Study to Learn About the Medicine Called Nirmatrelvir Used in Combination With Ritonavir in People with Weakened Immune Systems or at Increased Risk for Poor Outcomes who are Hospitalized Due to Severe COVID-19
- Conditions
- Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), Coronavirus Disease 2019 (COVID-19), Immunocompromised, Hospitalization
- Trial name
- EPIC-HOS (NCT05545319)
- Testing
- Nirmatrelvir, Ritonavir
- Where
- 11 sites in United States, Bulgaria
- Sponsor
- Pfizer
Chronic Hepatitis C
Real World Evidence of the Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C - An Observational Study in Germany (LIFE-C)
The interferon-free combination regimen of paritaprevir/r - ombitasvir with or without dasabuvir (ABBVIE REGIMEN) ± ribavirin (RBV) for the treatment of chronic hepatitis C (CHC) has been shown to be safe and effective in…
- Trial name
- LIFE-C (NCT02615145)
- Volunteers
- 472 people
- Sponsor
- AbbVie